General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-02 | 2024-03 | -0.18 | -0.2 | -0.02 | -11.11% |
2024-03-11 | 2023-12 | -0.23 | -0.2 | 0.03 | 13.04% |
2023-11-08 | 2023-09 | -0.22 | -0.21 | 0.01 | 4.55% |
2023-08-03 | 2023-06 | -0.17 | -0.22 | -0.05 | -29.41% |
2023-05-02 | 2023-03 | -0.17 | -0.17 | N/A | N/A |
2023-03-02 | 2022-12 | -0.14 | -0.16 | -0.02 | -14.29% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-05-30 | Citigroup | Upgrade | Buy | Buy |
2023-05-29 | Needham | Upgrade | Hold | |
2023-03-06 | Jefferies | Upgrade | Hold | |
2022-11-21 | Citigroup | Upgrade | Buy | Buy |
2022-08-11 | Piper Sandler | Upgrade | Overweight | |
2022-06-30 | Citigroup | Upgrade | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-04-25 | AMOUYAL PHILIPPE J | Director | 248.36K | Conversion of Exercise of derivative security |
2024-03-12 | ARTAL INTERNATIONAL S.C.A. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Stock Award(Grant) |
2024-04-25 | BARKER SAMUEL L | Director | 87.65K | Conversion of Exercise of derivative security |
2024-02-27 | COATS LONNEL | Chief Executive Officer | 1.10M | Conversion of Exercise of derivative security |
2024-04-25 | DEBBANE RAYMOND | Director | 6.80M | Conversion of Exercise of derivative security |
2024-04-25 | LEFKOWITZ ROBERT J | Director | 48.36K | Conversion of Exercise of derivative security |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Artal Group S.A. | 117.55M | 269.20M | 48.00% |
2023-06-29 | BVF Inc. | 20.00M | 45.79M | 8.16% |
2023-06-29 | FMR, LLC | 8.51M | 19.49M | 3.47% |
2023-06-29 | Vanguard Group Inc | 6.46M | 14.79M | 2.64% |
2023-06-29 | Blackrock Inc. | 6.38M | 14.61M | 2.60% |
2023-06-29 | JP Morgan Chase & Company | 2.93M | 6.71M | 1.20% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 3.70M | 8.48M | 1.51% |
2023-08-30 | Fidelity Growth Company Fund | 2.53M | 4.35M | 1.03% |
2023-08-30 | iShares Russell 2000 ETF | 2.15M | 3.69M | 0.88% |
2023-06-29 | JP Morgan Small Cap Value Fund | 1.43M | 3.27M | 0.58% |
2023-06-29 | Vanguard Extended Market Index Fund | 1.42M | 3.25M | 0.58% |
2023-08-30 | Fidelity Select Portfolios - Biotechnology | 1.09M | 1.87M | 0.44% |
Split | Date |
---|---|
1 : 7 | 2015-05-21 |
On the bright side, Lexi is rated a strong buy on Nasdaq.com, with a low target of $4, consensus of $6.33
I think that low number has gone up recently from $2.50 If memory serves me
Honestly I’ll take the low of $4, that will double my money and then I can sell half and let the houses money ride through LX9211 fate, which ultimately I think the most important driver for all .
If we get a new CEO with they same level of experience as we got with Tom, when they announce new coverage ( they said it was coming really soon) the new shorts may regret entering this trade.
Also, when they actually file for T1 and when they actually enter P3 for HCM, I would think the SP would pop?
Seems like at least 4 short term mini catalyst could be on the horizon, could be wrong, but at the end of the day, when we enter P3 with Lx9211, I think this SP is going to be significantly higher than today.
Possible driver of near term SP
CEO announcement very soon would seem very timely given recent $250 m raise ( had to be part over the conversations, no? Coats had his last call and retiring in about 45 days so we should have some overlap with new and old CEO) share holder meeting May 10th, NSM May 13-17, June 1st a key time around new access ( from recent call “ very shortly expecting more coverage”), July 1 mid year point, should have actual T1 submission and actual P3 commencement for HCM. To boot we are sitting at 20 m short with 9 days to cover, I’m not sure sure there is going to be a better reentry point than where we are at now under $2 with all that on the very near term.
Thoughts?
Next catalyst, a new high powered CEO. Could be this week or next. ( or was Coats departure a complete surprise to Lexi and their recent cohort of investors, not likely) With strong financial backing, a solid COO, and amazing pipeline lined up, Lexi is ready to rip again, especially with 20m short and 9 days to cover. Last time we were at 9 days was mid Jan……
May is going to be very interesting,
Lexi has over 20 m short with 9 days to cover.
If your short right now, would you want to hold right now and wait to hear who gets announced as the new CEO?
With backing and a pipeline like they have the new CEO could be someone very creditable and send shares soaring. If I’m short I’d buy back right now, make my profit and wait and see.
I see a bit of a run over the next week or two , could be wrong? Thoughts? Why stay short , ( in May) how much lower would you be waiting for us to go in the short term with the cash and opportunities in front of us?
The market is telling us this company is for sale
All they need to say at this point is: we have no clue how to run a business thus we are for sale.
I think we all have suffered enough with LXRX so far. One bit of good news would be so welcome after all those years.
Nasdaq.com new consensus is Strong Buy, with price target of 6.33, low of $4 and high of $10
These are the analyst that are on earnings calls and know the company best.
Coats vacating CEO right after huge capitol raise feeling like some type of partnership is close, sales not going as planned for Impefa, I think they know now they need to partner with a big pharma to get more coverage or on formularies. T1 addition by year end is going to require a larger sales force, and without Impefa sales to support, partnership needed or cash burn is going to be too great. I liked Lexicon in July of last years and since then there has been continuous strengthening of this company, from management to new indication potentials.